Kestra Showcases Accelerated Innovation at HRS 2026
Rhea-AI Summary
Kestra (Nasdaq: KMTS) will exhibit at Heart Rhythm 2026 in Chicago April 23–26 and showcase its Cardiac Recovery System and ASSURE WCD platform.
The company highlights ACE-PAS, the largest prospective wearable defibrillator study, and is launching an FDA-approved ASSURE WCD algorithm update. Visit Booth 2119 to review clinical data and product demos.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – KMTS
On the day this news was published, KMTS gained 2.44%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $34M to the company's valuation, bringing the market cap to $1.43B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows mixed moves among medical-instrument peers: STAA down 4.49%, ANGO down 3.45%, AZTA down 4.87%, while ATRC is up 5.96%. Sector summary notes 3 peers moving with median change around -4.5%, suggesting broader dynamics but KMTS’s own direction is not specified.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Workplace award | Positive | -1.9% | Named a 2026 USA TODAY Top Workplaces award winner highlighting culture. |
| Mar 25 | IPO deal accolade | Positive | -0.6% | Recognized as GeekWire “Deal of the Year” finalist for 2025 IPO. |
| Mar 17 | Q3 FY2026 results | Positive | -7.4% | Reported 63% YoY revenue growth, higher margins, and raised guidance. |
| Mar 03 | Earnings date set | Neutral | +0.8% | Announced timing and webcast details for upcoming Q3 FY2026 report. |
| Jan 13 | Clinical collaboration | Positive | -5.8% | Announced Biobeat collaboration and $5M equity investment to enhance WCD data. |
Recent positive operational and recognition news has often been followed by negative price reactions, indicating a pattern of selling into good news.
Over the last six months, Kestra reported strong Q3 FY2026 growth with revenue of $24.6M, gross margin of 52.6%, and raised FY2026 revenue guidance to $93M, yet the stock fell 7.38% the next day. Strategic steps included a Biobeat collaboration with a $5M equity investment and integration of ambulatory blood pressure monitoring, alongside cultural and capital-markets recognition via USA TODAY Top Workplaces and a GeekWire “Deal of the Year” finalist nod. Those recognition headlines also saw modest negative price reactions, so today’s HRS 2026 innovation showcase fits into a backdrop of operational momentum but cautious trading.
Regulatory & Risk Context
An automatic shelf registration on April 1, 2026 under Form S-3ASR allows Kestra, as a well-known seasoned issuer, to offer and sell common shares from time to time once effective. The filing has usage_count = 0, so no takedowns have been disclosed yet. The shelf remains effective through 2029-04-01 unless otherwise updated.
Market Pulse Summary
This announcement spotlights Kestra’s Cardiac Recovery System and an FDA-approved ASSURE WCD algorithm update being showcased at HRS 2026, reinforcing its focus on connected SCA risk management. ACE-PAS data and clinician adoption are central to the story. In context of recent strong revenue growth, raised guidance to $93M, and strategic collaborations, key watchpoints include ongoing clinical performance data, uptake trends for ASSURE prescriptions, insider trading activity, and any future use of the existing S-3ASR shelf registration.
Key Terms
sudden cardiac arrest medical
sca medical
post-approval study regulatory
algorithm technical
fda-approved regulatory
AI-generated analysis. Not financial advice.
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it will exhibit at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society (HRS) taking place April 23–26 in Chicago. The company will showcase its Cardiac Recovery System® platform—a modern, integrated approach to managing sudden cardiac arrest (SCA) risk that unites proven therapy, actionable clinical insights, and ongoing patient support to enhance protection and optimize care.
Kestra, one of the fastest-growing companies in medical technology, continues to build momentum as clinicians increasingly shift toward more connected approaches to SCA risk management. At HRS, attendees will see why more clinicians are turning to Kestra to improve patient protection and better manage risk during the most vulnerable stages of recovery.
The ASSURE® WCD is at the center of the Cardiac Recovery System platform. Insights from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS)—the largest prospective study of wearable defibrillators to date—demonstrate robust real-world performance and continue to guide innovation across the platform. At HRS, Kestra is launching a recently FDA-approved ASSURE WCD algorithm update that builds on market-leading clinical performance and applies real-world data to further enhance patient protection and advance care.
“At Kestra, innovation is a core principle, so we are excited to further advance the clinical benefits of the ASSURE WCD with this new algorithm. We’re seeing a clear shift in how clinicians approach SCA risk, with a growing emphasis on patient compliance and connected models of care,” said Brian Webster, President and Chief Executive Officer. “HRS is a pivotal moment to engage with prescribers and demonstrate how our clinically informed innovation is driving that momentum—delivering meaningful improvements for clinicians and their patients.”
Kestra will be located at Booth 2119, where attendees can experience the ASSURE system firsthand, explore the Cardiac Recovery System platform through an immersive multimedia experience, and review clinical data from ACE-PAS.
About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.
Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of April 22, 2026. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 17, 2025, and in other periodic reports filed by Kestra with the SEC. These filings are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93288f45-4a54-4de1-b66e-207047603f80
Media contact Rhiannon Pickus rhiannon.pickus@kestramedical.com Investor contact Neil Bhalodkar neil.bhalodkar@kestramedical.com